0.9639
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché ITRM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.968
Aprire:
$0.97
Volume 24 ore:
491.96K
Relative Volume:
1.07
Capitalizzazione di mercato:
$41.60M
Reddito:
-
Utile/perdita netta:
$-35.58M
Rapporto P/E:
-0.3637
EPS:
-2.65
Flusso di cassa netto:
$-42.82M
1 W Prestazione:
-5.50%
1M Prestazione:
+0.41%
6M Prestazione:
-49.27%
1 anno Prestazione:
-13.94%
Iterum Therapeutics Plc Stock (ITRM) Company Profile
Nome
Iterum Therapeutics Plc
Settore
Industria
Telefono
(872) 225-6077
Indirizzo
3 DUBLIN LANDINGS, DUBLIN 1
Confronta ITRM con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
ITRM
Iterum Therapeutics Plc
|
0.9639 | 41.60M | 0 | -35.58M | -42.82M | -2.65 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Iterum Therapeutics Plc Stock (ITRM) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2021-05-28 | Aggiornamento | Gabelli & Co | Sell → Hold |
2021-03-15 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
2020-06-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
2020-01-21 | Downgrade | Gabelli & Co | Buy → Sell |
2019-12-11 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
2019-06-21 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Iterum Therapeutics Plc Borsa (ITRM) Ultime notizie
Transcript : Iterum Therapeutics plcSpecial Call - MarketScreener
Research Analysts Set Expectations for ITRM FY2026 Earnings - Defense World
Two Sigma Investments LP Invests $45,000 in Iterum Therapeutics plc (NASDAQ:ITRM) - Defense World
EVERSANA expands commercialisation portfolio with OS Therapies and Iterum Therapeutics partnerships - pharmaphorum
Citadel Advisors LLC Acquires Shares of 21,207 Iterum Therapeutics plc (NASDAQ:ITRM) - Defense World
Iterum Therapeutics (ITRM) Partners with EVERSANA for U.S. Launc - GuruFocus
Iterum Therapeutics announces partnership with EVERSANA - PharmaLive
Iterum Therapeutics inks deal for ORLYNVAH commercialization By Investing.com - Investing.com Nigeria
Iterum Therapeutics inks deal for ORLYNVAH commercialization - Investing.com
Iterum Therapeutics Announces Partnership for Commercialization Services - Yahoo Finance
Pfizer grants Iterum payment extension for FDA-approved antibiotic By Investing.com - Investing.com South Africa
Pfizer grants Iterum payment extension for FDA-approved antibiotic - Investing.com Australia
Iterum Therapeutics Announces Extension of Term of Promissory No - GuruFocus
Iterum Therapeutics (ITRM) Extends $20M Payment Deadline with Pf - GuruFocus
Iterum Therapeutics Announces Extension of Term of Promissory Note | ITRM Stock News - GuruFocus
Iterum Therapeutics Announces Extension of Term of Promissory Note - The Manila Times
Iterum Therapeutics Announces Extension of $20 Million Regulatory Milestone Payment Deadline with Pfizer to 2029 - Nasdaq
Iterum Gains 3-Year Extension on $20M Pfizer Payment, Strengthens ORLYNVAH Launch Strategy - Stock Titan
Iterum targets ORLYNVAH US launch by Q4 2025 while extending cash runway into 2026 - MSN
When Will Iterum Therapeutics plc (NASDAQ:ITRM) Become Profitable? - simplywall.st
Iterum Therapeutics plc (NASDAQ:ITRM) Q1 2025 Earnings Call Transcript - Insider Monkey
Iterum Therapeutics PLC (ITRM) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial ... - Yahoo Finance
Iterum Therapeutics PLC (ITRM) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial Stability Amidst Market Challenges - GuruFocus
Iterum Therapeutics PLC (ITRM) Q1 2025 Earnings Call Highlights: - GuruFocus
ITRM Plans Fourth-Quarter Launch for ORLYNVAH in UTI Treatment | - GuruFocus
Iterum Therapeutics (ITRM) Projects Adequate Funding Until 2026 - GuruFocus
Iterum Therapeutics plc SEC 10-Q Report - TradingView
Iterum Therapeutics Reports First Quarter 2025 Financial Results - The Manila Times
Transcript : Iterum Therapeutics plc, Q1 2025 Earnings Call, May 13, 2025 - marketscreener.com
Q1 Earnings Estimate for ITRM Issued By HC Wainwright - Defense World
Iterum Therapeutics’ (ITRM) Buy Rating Reiterated at HC Wainwright - Defense World
Iterum Therapeutics plc (NASDAQ:ITRM): When Will It Breakeven? - Yahoo Finance
Iterum Therapeutics (ITRM) to Release Quarterly Earnings on Monday - Defense World
Iterum Therapeutics (ITRM) Receives Buy Rating from HC Wainwrigh - GuruFocus
Iterum Therapeutics (ITRM) Receives Buy Rating from Analyst | IT - GuruFocus
Iterum Therapeutics to Report First Quarter 2025 Financial Results on May 13, 2025 - Yahoo Finance
Iterum Therapeutics Earnings Coming May 13: Next-Gen Antibiotics Developer Sets Q1 2025 Update - Stock Titan
Renaissance Technologies LLC Purchases Shares of 438,816 Iterum Therapeutics plc (NASDAQ:ITRM) - Defense World
Check Out Iterum Therapeutics Plc (ITRM)’s Trade Data Rather Than the Analysts’ Views - Sete News
Iterum Therapeutics Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares - The Manila Times
Iterum Therapeutics Raises $5M from Single Investor: Major Push for Antibiotic Commercialization - Stock Titan
Iterum Therapeutics Plc: Rising -64.90% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com
Iterum Therapeutics Plc (ITRM) Becoming More Attractive for Investors - knoxdaily.com
Iterum Therapeutics (ITRM) Secures $5 Million in Direct Offering - GuruFocus
Evaluating ITRM’s financial ratios for a profitable investment - uspostnews.com
Iterum Therapeutics secures $5 million in direct offering - Investing.com
Iterum Therapeutics Announces $5 Million Registered Direct Offering Of Ordinary Shares - marketscreener.com
Iterum Therapeutics plc Announces Definitive Agreement for $5 Million Registered Direct Offering of Shares - Nasdaq
Iterum Therapeutics Secures Critical $5M Funding: ORLYNVAH Drug Launch Plans Accelerate - Stock Titan
ITRM’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
Iterum Therapeutics Plc (NASDAQ:ITRM) Shares Surged 24.11% In A Week – But Can It Maintain Its Gains? - Marketing Sentinel
Iterum Therapeutics Plc Azioni (ITRM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):